Takeda Pharmaceutical Co Ltd（TAK）财务数据TAKTakeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited (TAK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Gastrointestinal diseases, accounting for 31.6% of total sales, equivalent to JPY 386.10B. Other significant revenue streams include Plasma derivatives and Rare diseases. Understanding this composition is critical for investors evaluating how TAK navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Takeda Pharmaceutical Company Limited maintains a gross margin of 58.01%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.95%, while the net margin is 9.28%. These profitability ratios, combined with a Return on Equity (ROE) of -2.27%, provide a clear picture of how effectively TAK converts its operational activities into shareholder value.

In the context of the broader market, TAK competes directly with industry leaders such as NVO and LLY. With a market capitalization of $56.30B, it holds a significant position in the sector. When comparing efficiency, TAK's gross margin of 58.01% stands against NVO's 78.21% and LLY's 85.78%. Such benchmarking helps identify whether Takeda Pharmaceutical Company Limited is trading at a premium or discount relative to its financial performance.

Takeda has shown a gross margin of 58.01% in Q1 2027, indicating strong profitability potential. However, the company has experienced significant fluctuations in net income, including a loss of 368.47 billion JPY in Q4 2026, which raises concerns about financial stability.